開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9939)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSING IN CHINA IN PHASE III CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF COVID-19 OUTPATIENTS

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that on 10 February 2022, the multi-regional phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients (the "**Phase III Clinical Trial**") has enrolled and dosed the first patient in China in the Third People's Hospital of Shenzhen (深圳市第三人民醫院).

The Phase III Clinical Trial is a randomized, double-blind, placebo-controlled, multi-regional study, designed to evaluate the efficacy and safety of proxalutamide in male COVID-19 outpatients. The trial has enrolled nearly 200 patients in the countries including Brazil, the Philippines and Malaysia. China is one of the key countries participating in the Phase III Clinical Trial, which was approved by the China National Medical Products Administration (NMPA) on 1 September 2021. The sites participating in this trial in China include Beijing Ditan Hospital (北京地壇醫院), China-Japan Friendship Hospital (中日友好醫院), the Third People's Hospital of Shenzhen (深圳市第三人民醫院), Shanghai Public Health Clinical Center (上海市公共衛生臨床中心), Hangzhou Xixi Hospital (杭州市西溪醫院), the Public Health Clinical Center of Chengdu (成都市公共衛生臨床中心) and the Fifth People's Hospital of Suzhou (蘇州市第五人民醫院).

In addition, the clinical trial for COVID-19 inpatients (NCT05009732) has initiated patient enrollment in the United States, Ukraine and the Philippines, and is currently conducting patients screening before enrollment in China sites. The Group is also actively carrying forward the process in the rest of countries participating in the global multi-regional clinical trials.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 11 February 2022

As of the date of this announcement, the executive Director is Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*